American Journal of Cardiology
Volume 105, Issue 8 , Pages 1140-1146 , 15 April 2010

Influence of Renal Function on the Use of Guideline-Recommended Therapies for Patients With Heart Failure

  • J. Thomas Heywood, MD

      Affiliations

    • Scripps Clinic, La Jolla, California
    • Corresponding Author InformationCorresponding author: Tel: (858) 554-5588; fax: (858) 554-5197
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • University of California, Los Angeles, Medical Center, Los Angeles, California
    • ,
  • Clyde W. Yancy, MD

      Affiliations

    • Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas
    • ,
  • Nancy M. Albert, PhD, RN

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Anne B. Curtis, MD

      Affiliations

    • University of South Florida College of Medicine, Tampa, Florida
    • ,
  • Wendy Gattis Stough, PharmD

      Affiliations

    • Campbell University School of Pharmacy, Research Triangle Park, North Carolina
    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Northwestern University, Feinberg School of Medicine, Chicago, Illinois
    • ,
  • Mark L. McBride, PhD

      Affiliations

    • Outcome Sciences, Inc., Cambridge, Massachusetts
    • ,
  • Mandeep R. Mehra, MD

      Affiliations

    • University of Maryland, Baltimore, Maryland
    • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Dwight Reynolds, MD

      Affiliations

    • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
    • ,
  • Mary Norine Walsh, MD

      Affiliations

    • The Care Group, LLC, Indianapolis, Indiana

Received 19 October 2009 ,Revised 3 December 2009 ,Accepted 3 December 2009.

References 

  1. Fonarow GC, Heywood JT. The confounding issue of comorbid renal insufficiency. Am J Med. 2006;119:S17–S25
  2. Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008;36:S75–S88
  3. Saltzman HE, Sharma K, Mather PJ, Rubin S, Adams S, Whellan DJ. Renal dysfunction in heart failure patients: what is the evidence?. Heart Fail Rev. 2007;12:37–47
  4. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97
  5. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004;44:1593–1600
  6. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587–1592
  7. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators (Renal function as a predictor of outcome in a broad spectrum of patients with heart failure). Circulation. 2006;113:671–678
  8. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). A.D.H.E.R.E. Scientific Advisory Committee and Investigators Am Heart J. 2005;149:209–216
  9. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–1996
  10. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail. 2006;12:257–262
  11. Lahoz C, Mostaza JM, Mantilla MT, Taboada M, Tranche S, Lopez-Rodriquez I, et al. Achievement of therapeutic goals and utilization of evidence-based cardiovascular therapies in coronary heart disease patients with chronic kidney disease. Am J Cardiol. 2008;101:1098–1102
  12. Patel UD, Hernandez AF, Liang L, Peterson ED, LaBresh KA, Yancy CW, et al. Quality of care and outcomes among patients with heart failure and chronic kidney disease: a Get With the Guidelines–Heart Failure Program study. Am Heart J. 2008;156:674–681
  13. Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J. 2007;153:1064–1073
  14. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gattis Stough W, Gheorghiade M, et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail. 2008;1:98–106
  15. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gattis Stough W, Gheorghiade M, et al. Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. Am Heart J. 2007;154:12–38
  16. Spertus JA, Eagle KA, Krumholtz H, Mitchell KR, Normand SL. American College of Cardiology/American Heart Association Task Force on Performance Measures. American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. J Am Coll Cardiol. 2005;45:1147–1156
  17. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016
  18. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices; American Association for Thoracic Surgery; Society of Thoracic Surgeons (ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons). J Am Coll Cardiol. 2008;51:e1–e62
  19. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society of Heart and Lung Transplantation; Heart Rhythm Society (ACC/AHA 2005 Guideline for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)). Circulation. 2005;112:e154–e235
  20. Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724–731
  21. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?. J Am Geriatr Soc. 2002;50:1297–1300
  22. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288–296
  23. Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with left ventricular dysfunction. Am J Cardiol. 2006;98:485–490
  24. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–1384

 The IMPROVE HF registry and this study were sponsored by Medtronic, Inc., Minneapolis, MN.

 The authors served as consultants to Medtronic, Inc.; as of June 2008, this association ended for Dr. Yancy.

 Dr. McBride is a consultant to Outcome Sciences, Inc., Cambridge, Massachusetts.

PII: S0002-9149(09)02846-X

doi: 10.1016/j.amjcard.2009.12.016

American Journal of Cardiology
Volume 105, Issue 8 , Pages 1140-1146 , 15 April 2010

Article Tools

* Image Usage & Resolution